摘要
他莫昔芬(tamoxifen)为非固醇类抗雌激素药物,目前临床广泛用于雌激素受体(ER)阳性的乳腺癌防治,但其不良反应显著。体内他莫昔芬经细胞色素P450(CYP)同工酶代谢,存在个体差异。其药物代谢遗传多态性已引起普遍关注。本文简要分析他莫昔芬的遗传药理学研究近况及其临床应用进展。
Tamoxifen is a non-steroidal anti-estrogen drug,which is currently widely used for estrogen receptor (ER)-positive breast cancer prevention and treatment.It has reported that some patients have obvious adverse reactions. The metabolism of tamoxifen is by the enzyme cytochrome P450(CYP),and there are significant individual differences. Tamoxifen has raised awareness of the genetic polymorphism of drug metabolism of common concern.
出处
《世界临床药物》
CAS
2009年第11期698-701,共4页
World Clinical Drug
关键词
他莫昔芬
遗传药理学
临床应用
乳腺癌
tamoxifen
pharmacogenetics
clinical application
breast cancer
